William Hrushesky to Recombinant Proteins
This is a "connection" page, showing publications William Hrushesky has written about Recombinant Proteins.
Connection Strength
0.164
-
Guideline-based peer-to-peer consultation optimizes pegfilgrastim use with no adverse clinical consequences. Am J Manag Care. 2012 05 01; 18(5):e168-72.
Score: 0.085
-
Tale of Two Erythropoiesis-Stimulating Agents: Utilization, Dosing, Litigation, and Costs of Darbepoetin and Epoetin Among South Carolina Medicaid-Covered Patients With Cancer and Chemotherapy-Induced Anemia. J Oncol Pract. 2017 06; 13(6):e562-e573.
Score: 0.030
-
Erythropoietin usage in patients with cancer. Cancer J Sci Am. 1995 Nov-Dec; 1(4):243-6.
Score: 0.027
-
Timing may be a critical factor in drug therapy. Cancer Treat Rep. 1987 Dec; 71(12):1321.
Score: 0.016
-
Irreversible inactivation of interleukin 2 in a pump-based delivery environment. Proc Natl Acad Sci U S A. 1996 May 28; 93(11):5460-5.
Score: 0.007